The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Male or female, ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF).
Histologically or cytologically confirmed NSCLC.
No prior systemic anti-tumor therapy.
No prior local therapy for NSCLC.
Tumor histology or cytology confirming combined small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma or squamous cell carcinoma components of more than 10%.
Participants with other malignant tumors within 3 years prior to randomization.
Resting electrocardiogram (ECG) showing clinically significant abnormal results.
Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.